EVALUATION OF THE ANTICONVULSANT ACTIVITY OF N-ACETYLGLUCOSAMINE IN A MICE MODEL

ABSTRACT

Background: Epilepsy is a neurological disorder characterized by recurrent seizures resulting from abnormal brain activity. Despite the availability of antiepileptic drugs (AEDs), many patients experience drug resistance and adverse effects, highlighting the need for alternative therapeutic options. Objective: The aim of this study is to assess the anticonvulsant potential of GlcNAC in different seizure models and compare its effects with standard anticonvulsant drugs, Diazepam and Phenobarbital. Methods: Seventy-five Swiss albino mice (18-30g) were divided into five groups. Groups received both distilled water, various doses of GlcNAC, with Diazepam (2 mg/kg) and Phenobarbital (10 mg/kg) serving as positive controls. Three seizure models; Pentylenetetrazol (PTZ), Maximal Electroshock Seizure (MES), and Strychnine were used to evaluate seizure onset, duration, and level of protection. Results: The PTZ and Strychnine models showed no significant differences in seizure onset or duration between GlcNAC-treated groups and controls, indicating a lack of anticonvulsant activity in these models. However, in the MES model, the 400 mg/kg dose of GlcNAC significantly improved seizure protection and recovery time, demonstrating dose-dependent anticonvulsant potential. Conclusion: The findings suggest that while GlcNAC does not significantly prevent seizure onset in PTZ and Strychnine models, it may exert a neuroprotective effect in the MES model, particularly at higher doses. This dose-dependent anticonvulsant activity highlights the potential of GlcNAC as an adjunct therapy for epilepsy. Further studies are required to explore its long-term effects, molecular mechanisms, and optimal dosing for clinical application.